A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study

Table 4 Historical Survival Data of the Patients with BVI, LyVI or LVI Positive Stage IA NSCLC

Author	Year	T-Classification	Vessel invasion status	Number of Patients	5-year Survival Rates (%)
Author	Year	T-Classification	Vessel invasion status	Number of Patients	Overall	Relapse free
Pechet et al. [6]	2004	T1	BVI	22	28	–
Tsuchiya et al. [9]	2007	T1	LVI (BVI or LyVI)	85	71.8	–
Tsuchiya et al. [10]	2007	T1	LVI (BVI or LyVI)	144	78.7	–
Miyoshi et al. [11]	2009	T1	LVI (BVI or LyVI)	62	78	–
Funai et al. [12]	2011	T1	LyVI	22	70.9	–
Ito et al. [16]	2012	T1	LVI (BVI or LyVI)	105	–	58
Shimada et al. [14]	2012	T1	BVI	116	72.1	71.3
Shimada et al. [14]			LyVI	122	76.4	76.1
Kudo et al. [17]	2013	T1a	BVI	38	87.1	72.5
Kudo et al. [17]		T1b	BVI	39	65.9	58.9
Hamanaka et al. [19]	2015	T1	LVI (BVI or LVI)	56	–	79.7
Present series	2018	T1	LVI (BVI or LVI)	52	94.2	88.5

BVI Blood vessel invasion, LVI Lymphovascular invasion, LyVI Lymphatic vessel invasion

ISSN: 1471-2407